Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells

Pancreatic adenocarcinoma has an exceedingly poor prognosis, accounting for five-year survival of less than 5%. Presently, improving the efficacy of pancreatic adenocarcinoma treatment has been the focus of medical researchers worldwide. Recently, it has been suggested that deregulation of interleuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Hai-Bo, Tong, Meng-Ting, Wang, Jing, Hu, Hong, Zhai, Chong-Ya, Huang, Chang-Xin, Li, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859857/
https://www.ncbi.nlm.nih.gov/pubmed/29693005
http://dx.doi.org/10.1155/2018/3195025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859857/
https://www.ncbi.nlm.nih.gov/pubmed/29693005
http://dx.doi.org/10.1155/2018/3195025

Ejemplares similares